Status:
COMPLETED
Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
EARLY_PHASE1
Brief Summary
We hypothesize that 18FDG Positron Emission Tomography (FDG PET) imaging, carried out after the first cycle of chemotherapy, will identify responders, thus permitting early termination of potential to...
Eligibility Criteria
Inclusion
- Histologically proven ovarian cancer at diagnosis of any stage.
- Patients with evidence of disease that is radiographically measurable (CT scan)
- Patients have planned to undergo standard chemotherapy. Dose and schedule will be determined per treating physician
Exclusion
- Patients with any other malignancy active within 5 years except for non-melanoma skin cancer, or carcinoma in situ of the cervix.
- Patients with an active infection
- Patients of childbearing potential are excluded from this study.
- Patients who have expected survival \< 3 months.
- Patients not planning or able to receive the outlined chemotherapy regimen as part of standard practice.
- Patient unable to complete study
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00620243
Start Date
June 1 2004
End Date
November 1 2008
Last Update
January 9 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065